TCMD (TCMD)
Quantitative Summary
DeterministicStrong operational fundamentals (Piotroski 7/9).
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe company demonstrates robust capital efficiency with an ROIC of 11.0%, suggesting a healthy spread over typical risk-free rates, while the DuPont components indicate that high gross margins at 75.9% are the primary driver of profitability rather than asset turnover or financial leverage. Fundamental integrity is further supported by strong qualitative signals: a Piotroski F-Score of 7/9 reflects solid operational improvements and balance sheet health, whereas the Beneish M-Score of -2.84 points to an extremely low probability of earnings manipulation. These metrics collectively portray a business with stable cash generation capabilities underpinned by superior pricing power relative to its cost structure.
Valuation analysis reveals a current P/E multiple of 27.5x, which requires contextualization against historical ranges and sector peers to determine if the market is pricing in aggressive growth expectations or premium quality characteristics. A DCF model implies an intrinsic fair value of $67; comparing this figure directly to current trading levels helps assess whether the stock is trading at a discount due to temporary headwinds or at a premium reflecting anticipated acceleration in revenue, which has grown 12.5% year-over-year. The divergence between the implied DCF target and market price encapsulates the consensus view on future growth sustainability versus present valuation multiples.
The data does not provide specific risk factor deltas, insider transaction records, or Fama-French alpha measurements to further refine the risk-reward profile beyond the fundamental scores already analyzed. Consequently, the investment case rests entirely on the interpretation of whether the 12.5% revenue expansion can sustainably support the elevated multiple and justify the gap between current market pricing and the $67 fair value estimate derived from discounted cash flow assumptions.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
InteractiveSensitivity Matrix
| TG ↓ / WACC → | 8% | 10% | 12% |
|---|---|---|---|
| 2% | $81 | $60 | $48 |
| 3% | $95 | $67 | $52 |
| 4% | $115 | $76 | $57 |
Center = base case. Green = >10% upside, Red = >10% downside vs —.
Pre-computed DCF: WACC=10.0%, terminal growth 3%. Fair value $67 (+0.0%). Not investment advice.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
ETF Contagion Visualizer
Simulate a price drop in TCMD to visualize passive redemption contagion across ETFs and collateral stocks.
If TCMD (TCMD) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Eli Lilly & Co. (LLY) as the most exposed collateral stock, sharing 3 ETFs with TCMD. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 4 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
TCMD Ownership Dynamics
ETFs with Highest TCMD Exposure
Float lock-up computed from 4 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
TCMD Capital Efficiency
How efficiently does TCMD convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
TCMD converts 103% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-06 | 4 | $24.05 | $96.2 |
| 2026-05-05 | 7 | $22.43 | $157.01 |
| 2026-04-28 | 3,544 | $24.24 | $85,906.56 |
| 2026-04-15 | 5 | $25.06 | $125.3 |
| 2026-04-02 | 461 | $25.97 | $11,972.17 |
| 2026-04-01 | 457 | $26.13 | $11,941.41 |
| 2026-03-24 | 93 | $26.51 | $2,465.43 |
| 2026-03-23 | 418 | $26.10 | $10,909.8 |
| 2026-03-20 | 200 | $27.07 | $5,414 |
| 2026-03-19 | 23 | $27.03 | $621.69 |
| 2026-03-17 | 2 | $27.30 | $54.6 |
| 2026-03-16 | 5 | $26.93 | $134.65 |
| 2026-03-06 | 94 | $29.41 | $2,764.54 |
| 2026-02-27 | 2,831 | $29.91 | $84,675.21 |
| 2026-02-03 | 330 | $28.73 | $9,480.9 |
| 2025-12-29 | 92 | $29.66 | $2,728.72 |
| 2025-12-17 | 2,090 | $28.95 | $60,505.5 |
| 2025-12-04 | 287 | $26.36 | $7,565.32 |
| 2025-11-17 | 235 | $23.70 | $5,569.5 |
| 2025-11-06 | 20 | $24.21 | $484.2 |
| 2025-11-05 | 144 | $22.18 | $3,193.92 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Compare TCMD to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.